학술논문
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
Document Type
Article
Author
Source
In Clinical Lung Cancer May 2021 22(3):e379-e389
Subject
Language
ISSN
1525-7304